Critical analysis of an oncolytic herpesvirus encoding granulocyte-macrophage colony stimulating factor for the treatment of malignant melanoma.

IF 6.7
Oncolytic Virotherapy Pub Date : 2014-01-15 eCollection Date: 2014-01-01 DOI:10.2147/OV.S36701
Tasha Hughes, Robert S Coffin, Caroline E Lilley, Rafael Ponce, Howard L Kaufman
{"title":"Critical analysis of an oncolytic herpesvirus encoding granulocyte-macrophage colony stimulating factor for the treatment of malignant melanoma.","authors":"Tasha Hughes,&nbsp;Robert S Coffin,&nbsp;Caroline E Lilley,&nbsp;Rafael Ponce,&nbsp;Howard L Kaufman","doi":"10.2147/OV.S36701","DOIUrl":null,"url":null,"abstract":"<p><p>Oncolytic viruses that selectively lyse tumor cells with minimal damage to normal cells are a new area of therapeutic development in oncology. An attenuated herpesvirus encoding the granulocyte-macrophage colony stimulating factor (GM-CSF), known as talimogene laherparepvec (T-VEC), has been identified as an attractive oncolytic virus for cancer therapy based on preclinical tumor studies and results from early-phase clinical trials and a large randomized Phase III study in melanoma. In this review, we discuss the basic biology of T-VEC, describe the role of GM-CSF as an immune adjuvant, summarize the preclinical data, and report the outcomes of published clinical trials using T-VEC. The emerging data suggest that T-VEC is a safe and potentially effective antitumor therapy in malignant melanoma and represents the first oncolytic virus to demonstrate therapeutic activity against human cancer in a randomized, controlled Phase III study. </p>","PeriodicalId":19491,"journal":{"name":"Oncolytic Virotherapy","volume":"3 ","pages":"11-20"},"PeriodicalIF":6.7000,"publicationDate":"2014-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/OV.S36701","citationCount":"24","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncolytic Virotherapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/OV.S36701","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2014/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 24

Abstract

Oncolytic viruses that selectively lyse tumor cells with minimal damage to normal cells are a new area of therapeutic development in oncology. An attenuated herpesvirus encoding the granulocyte-macrophage colony stimulating factor (GM-CSF), known as talimogene laherparepvec (T-VEC), has been identified as an attractive oncolytic virus for cancer therapy based on preclinical tumor studies and results from early-phase clinical trials and a large randomized Phase III study in melanoma. In this review, we discuss the basic biology of T-VEC, describe the role of GM-CSF as an immune adjuvant, summarize the preclinical data, and report the outcomes of published clinical trials using T-VEC. The emerging data suggest that T-VEC is a safe and potentially effective antitumor therapy in malignant melanoma and represents the first oncolytic virus to demonstrate therapeutic activity against human cancer in a randomized, controlled Phase III study.

Abstract Image

编码粒细胞-巨噬细胞集落刺激因子的溶瘤疱疹病毒治疗恶性黑色素瘤的关键分析。
溶瘤病毒选择性地裂解肿瘤细胞,对正常细胞的损伤最小,是肿瘤学治疗发展的一个新领域。一种编码粒细胞-巨噬细胞集落刺激因子(GM-CSF)的减毒疱疹病毒,被称为talimogene laherparepvec (T-VEC),已被确定为一种有吸引力的溶瘤病毒,用于癌症治疗,基于临床前肿瘤研究和早期临床试验的结果以及黑色素瘤的大型随机III期研究。在这篇综述中,我们讨论了T-VEC的基本生物学,描述了GM-CSF作为免疫佐剂的作用,总结了临床前数据,并报告了已发表的使用T-VEC的临床试验的结果。新出现的数据表明,T-VEC是一种安全且潜在有效的恶性黑色素瘤抗肿瘤疗法,是首个在随机对照III期研究中显示出对人类癌症治疗活性的溶瘤病毒。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
审稿时长
16 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信